SAM Medical Products Launches New Product to Control Junctional Hemorrhage
WILSONVILLE, Ore., April 3, 2013 /PRNewswire-iReach/ -- SAM Medical Products is pleased to announce it has received 510(k) regulatory clearance from the FDA for the release for sale of the SAM Junctional Tourniquet (SJT). Building upon the highly successful SAM Pelvic Sling II presently utilized by health care professionals around the world to immobilize pelvic fractures, the SJT is designed to also control bleeding where standard tourniquets would not be effective. Such wounds are typically junctional in nature, such as a high level leg amputation as a result of an IED blast injury. Time is of the essence for patients with these types of injuries, and the SJT's simple design allows application (in standard industry training models) for hemorrhage control in less than 25 seconds in most cases. Compact and lightweight, it can easily be carried in a medical bag or attached to a backpack.
Recent studies indicate that junctional hemorrhage accounts for up to 20% of preventable deaths in combat.1 The SAM Junctional Tourniquet was designed, using input from key military medical personnel, to treat these injuries by placing pressure on an artery to stop the flow of blood to a region of the body. The trademarked and patent pending innovative design utilizes a rugged Target Compression Device (TCD) which, once targeted by the medic, is inflated to apply the necessary amount of pressure. Each SJT can utilize up to two TCD's to treat bilateral injuries. The unique combination of both a mechanical belt buckle and a pneumatic TCD allow for quick application and effective, expedient hemorrhage control.